Iranian patients and families report steep increases in the prices of medicines and shortages of some treatments. Multiple outlets say the medicines market faces a supply squeeze, forcing people to search for alternatives or pay more for prescriptions.
The coverage links the situation to the impact of the US blockade and stepped-up sanctions, which outlets describe as constraining Iran’s pharmaceutical supply chain and production. The Economic Times and India Today both characterize the problem primarily as rising prices driven by sanctions-related supply pressures. The Independent, while also emphasizing sanctions and the US blockade, highlights the added hardship for patients, including difficulty finding certain treatments.
Across the reports, the core thread is the same: sanctions-related disruptions are reducing availability and increasing costs for medications in Iran. While the outlets vary slightly in emphasis—some focusing more on price dynamics and others on patient access—the underlying details point to the same drivers and outcomes.
